Gujarat Themis Biosyn Limited (BOM:506879)

India flag India · Delayed Price · Currency is INR
296.75
-4.20 (-1.40%)
At close: Mar 6, 2026
8.56%
Market Cap 30.76B
Revenue (ttm) 1.59B
Net Income (ttm) 477.89M
Shares Out 108.97M
EPS (ttm) 4.39
PE Ratio 64.36
Forward PE n/a
Dividend 0.67 (0.23%)
Ex-Dividend Date Sep 4, 2025
Volume 4,507
Average Volume 6,616
Open 301.90
Previous Close 300.95
Day's Range 290.10 - 301.90
52-Week Range 221.70 - 479.45
Beta -0.54
RSI 38.04
Earnings Date Feb 5, 2026

About Gujarat Themis Biosyn

Gujarat Themis Biosyn Limited engages in the manufacture of pharmaceuticals and medicinal chemicals in India. The company offers bulk drugs on job work basis in India. Its products include Rifamycin-S, an intermediate for the treatment of tuberculosis, Mycobacterium avium complex, leprosy, and Legionnaires' disease; Rifamycin-O for the treatment of traveler's diarrhea, irritable bowel syndrome, and hepatic encephalopathy; and Lovastatin. The company was incorporated in 1981 and is based in Mumbai, India. [Read more]

Industry Medicinal Chemicals and Botanical Products
Founded 1981
Employees 221
Stock Exchange Bombay Stock Exchange
Ticker Symbol 506879
Full Company Profile

Financial Performance

In fiscal year 2025, Gujarat Themis Biosyn's revenue was 1.51 billion, a decrease of -11.20% compared to the previous year's 1.70 billion. Earnings were 487.72 million, a decrease of -17.56%.

Financial Statements

News

Gujarat Themis Biosyn begins commercial production after major capacity expansion at Vapi facility

Gujarat Themis Biosyn Ltd has announced the successful completion of its fermentation block expansion at its manufacturing facility in Vapi,...

5 months ago - Business Upturn

Gujarat Themis Biosyn starts commercial production at new API plant in Vapi, Gujarat

Gujarat Themis Biosyn Ltd. has commenced commercial production at its newly established Active Pharmaceutical Ingredient (API) manufacturing facility located at 69/C, GIDC Industrial Estate, Vapi – 39...

10 months ago - Business Upturn

Themis Medicare shares surge nearly 2% following amalgamation announcement

Shares of Themis Medicare climbed 1.15% to ₹289.20 on the NSE as of 9:53 AM after the company announced its decision to merge Gujarat Themis Biosyn Limited (GTBL) with Themis Medicare Limited (TML). T...

1 year ago - Business Upturn